Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
NCT06499857 on ClinicalTrials.gov · last registry update 2025-11-14
A small phase 3 — 200 participants, against a typical 424. Due to report December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Time to first AF event detected by routine outpatient monitoring. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- University of Chicago
- Sponsor type
- Other
- Enrollment
- 200
- Started
- 2025-04-14
- Primary completion
- 2027-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to first AF event detected by routine outpatient monitoring
Conditions studied
Overweight or Obesity · Atrial Fibrillation
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.